Bendamustin (B) and rituximab (R) in the treatment of relapsed indolent CD 20+ non-Hodgkin-lymphoma - A phase II study of The East German Study Group of haematology and oncology (OSHO # 072)

被引：0
|
作者：
Lakner, V. [1 ]
Eschenburg, H. [1 ]
Aldaoud, A. [1 ]
Uhlig, J. [1 ]
机构：
[1] Praxis, Leipzig, Germany
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：209 / 210
页数：2
相关论文
共 50 条
  • [21] A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study
    Matsumoto, Kimihiro
    Takayama, Nobuyuki
    Aisa, Yoshinobu
    Ueno, Hironori
    Hagihara, Masao
    Watanabe, Kentaro
    Nakaya, Aya
    Chen, Kenko
    Shimizu, Takayuki
    Tsukada, Yuiko
    Yamada, Yuji
    Nakazato, Tomonori
    Ishida, Akaru
    Miyakawa, Yoshitaka
    Yokoyama, Kenji
    Nakajima, Hideaki
    Masuda, Yoshihiro
    Yano, Takahiro
    Okamoto, Shinichiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 554 - 562
  • [22] Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study
    Tobinai, Kensei
    Igarashi, Tadahiko
    Itoh, Kuniaki
    Kurosawa, Mitsutoshi
    Nagai, Hirokazu
    Hiraoka, Akira
    Kinoshita, Tomohiro
    Uike, Naokuni
    Ogura, Michinori
    Nawano, Shigeru
    Mori, Shigeo
    Ohashi, Yasuo
    CANCER SCIENCE, 2011, 102 (09) : 1698 - 1705
  • [23] Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
    Robinson, K. Sue
    Williams, Michael E.
    van der Jagt, Richard H.
    Cohen, Philip
    Herst, Jordan A.
    Tulpule, Anil
    Schwartzberg, Lee S.
    Lemieux, Bernard
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) : 4473 - 4479
  • [24] Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study
    Yosuke Matsumoto
    Tsutomu Kobayashi
    Yuji Shimura
    Eri Kawata
    Hisao Nagoshi
    Muneo Ohshiro
    Mio Sugitani
    Kazuho Shimura
    Toshiki Iwai
    Shin-ichi Fuchida
    Mihoko Yoshida
    Miki Kiyota
    Shinsuke Mizutani
    Yoshiaki Chinen
    Tomoko Takimoto-Shimomura
    Mitsushige Nakao
    Hiroto Kaneko
    Hitoji Uchiyama
    Nobuhiko Uoshima
    Hikari Nishigaki
    Yutaka Kobayashi
    Shigeo Horiike
    Chihiro Shimazaki
    Masafumi Taniwaki
    Junya Kuroda
    International Journal of Hematology, 2019, 110 : 77 - 85
  • [25] Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study
    Matsumoto, Yosuke
    Kobayashi, Tsutomu
    Shimura, Yuji
    Kawata, Eri
    Nagoshi, Hisao
    Ohshiro, Muneo
    Sugitani, Mio
    Shimura, Kazuho
    Iwai, Toshiki
    Fuchida, Shin-ichi
    Yoshida, Mihoko
    Kiyota, Miki
    Mizutani, Shinsuke
    Chinen, Yoshiaki
    Takimoto-Shimomura, Tomoko
    Nakao, Mitsushige
    Kaneko, Hiroto
    Uchiyama, Hitoji
    Uoshima, Nobuhiko
    Nishigaki, Hikari
    Kobayashi, Yutaka
    Horiike, Shigeo
    Shimazaki, Chihiro
    Taniwaki, Masafumi
    Kuroda, Junya
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (01) : 77 - 85
  • [26] A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma
    Luminari, Stefano
    Goldaniga, Maria
    Cesaretti, Marina
    Orsucci, Lorella
    Tucci, Alessandra
    Pulsoni, Alessandro
    Salvi, Flavia
    Arcaini, Luca
    Carella, Angelo Michele
    Tedeschi, Alessandra
    Pinto, Antonello
    Stelitano, Caterina
    Baldini, Luca
    LEUKEMIA & LYMPHOMA, 2016, 57 (04) : 880 - 887
  • [27] Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma
    Tobinai, K
    Watanabe, T
    Ogura, M
    Morishima, Y
    Ogawa, Y
    Ishizawa, KI
    Minami, H
    Utsunomiya, A
    Taniwaki, M
    Terauchi, T
    Nawano, S
    Matsusako, M
    Matsuno, Y
    Nakamura, S
    Mori, S
    Ohashi, Y
    Hayashi, M
    Seriu, T
    Hotta, T
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 174 - 180
  • [28] Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma
    Leahy, Michael F.
    Seymour, John F.
    Hicks, Rodney J.
    Turner, J. Harvey
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4418 - 4425
  • [29] Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study
    Sehn, Laurie H.
    Goy, Andre
    Offner, Fritz C.
    Martinelli, Giovanni
    Friedberg, Jonathan
    Lasserre, Susan F.
    Fine, Gregg
    Press, Oliver W.
    BLOOD, 2011, 118 (21) : 124 - 124
  • [30] RANDOMIZED PHASE II TRIAL COMPARING OBINUTUZUMAB (GA101) WITH RITUXIMAB IN PATIENTS WITH RELAPSED CD20+INDOLENT B-CELL NON-HODGKIN LYMPHOMA: PRELIMINARY ANALYSIS OF THE GAUSS STUDY
    Goy, A.
    Offner, F.
    Martinelli, G.
    Caballero, D.
    Gadeberg, O.
    Gaidano, G.
    Press, O.
    Fine, G.
    Chai, A.
    Sahin, D.
    Sehn, L.
    HAEMATOLOGICA, 2012, 97 : 322 - 323
12345